| First Author | Year | n | Duration (weeks) | Permitted Co-therapies | Interventions and Control | Quality Score |
| :----------- | :--- | :-- | :--------------- | :------------------------------------------------ | :--------------------------------------------------------------- | :------------ |
| Chan^27 | 2007 | 913 | 52 | Stable oral steroids,* stable inhaled steroids, theophylline, non-bronchodilator mucolytic preparations | Tiotropium 18 μg daily Placebo | 4 |
| Dusser^25 | 2006 | 1,010 | 48 | Short-acting β agonists, stable oral steroids,* stable inhaled steroids | Tiotropium 18 μg daily Placebo | 3 |
| Freeman^28 | 2007 | 395 | 13 | NA | Tiotropium 18 μg daily Placebo | 4 |
| Johansson^29 | 2008 | 224 | 13 | Salbutamol, oral steroids, and theophylline only for exacerbations | Tiotropium 18 μg daily Placebo | 3 |
| Moita^30 | 2008 | 311 | 13 | Salbutamol, long-acting β agonists, theophylline, mucolytics, stable oral steroids,* stable inhaled steroids | Tiotropium 18 μg daily Placebo | 4 |
| Niewoehner^24 | 2005 | 1,829 | 26 | Any (except for other open-label anticholinergic bronchodilators) | Tiotropium 18 μg daily Placebo | 4 |
| Tashkin^14 | 2008 | 5,993 | 208 | Any (except other inhaled anticholinergic bronchodilators) | Tiotropium 18 μg daily Placebo | 4 |
| Tonnel^31 | 2008 | 554 | 39 | Salbutamol, stable theophylline, stable mucolytics, stable oral steroids,* stable inhaled steroids | Tiotropium 18 μg daily Placebo | 5 |
| Verkindre^26 | 2006 | 100 | 13 | Salbutamol, theophylline, stable oral steroids,* inhaled steroids | Tiotropium 18 μg daily Placebo | 3 |
| Vogelmeier^32 | 2008 | 847 | 26 | Salbutamol, stable inhaled steroids | Tiotropium 18 μg daily + Formoterol 10 μg twice daily Placebo twice daily Tiotropium 18 μg + formoterol 10 μg twice daily | 5 |
| Voshaar^33 | 2008 | 719 | 13 | Salbutamol, stable theophylline, stable mucolytics, stable oral steroids,* stable inhaled steroids | Tiotropium 5μg + placebo 4 times daily Tiotropium 10 μg + placebo 4 times daily Ipratropium 36 μg 4 times daily Placebo daily | 4 |

* At a dose of ≤ 10 mg/day prednisone or equivalent
NA = not applicable

Table 2. Patients demographic characteristics of selected studies

| First Author | Year | Age (mean ± SD y) | Male (%) | Current Smoker (%) | Smoking History (mean ± SD pack-years) | COPD Duration (mean ± SD y) | FEV₁/FVC (mean ± SD %) | FEV₁ (mean ± SD % predicted) |
| :----------- | :--- | :---------------- | :------- | :----------------- | :------------------------------------- | :-------------------------- | :---------------------- | :-------------------------- |
| Brusasco^21  | 2003 | 64.2 ± 8.4        | 76.3     | NA                 | 43.8 ± 23.2                            | 9.6 ± 7.6                   | 43 ± 10                 | 39 ± 12                     |
| Casaburi^19  | 2002 | 65.0 ± 9.0        | 64.7     | NA                 | 61.0 ± 30.5                            | 8.4 ± 7.1                   | 46 ± 12                 | 34 ± 12                     |
| Casaburi^23  | 2005 | 66.6 ± 7.9        | 56.5     | 24.0               | 58.7 ± 33.0                            | 9.3 ± 7.1                   | 43 ± 11                 | 39 ± 14                     |
| Chan^27      | 2007 | 66.9 ± 8.9        | 60.0     | 31.0               | 50.6 ± 24.5                            | 9.9 ± 8.9                   | 46 ± 12                 | 39 ± 14                     |
| Dusser^25    | 2006 | 64.8 ± 9.3        | 88.0     | 25.5               | NA                                     | 8.4 ± 7.8                   | 55 ± 12                 | 48 ± 13                     |
| Freeman^28   | 2007 | 64.9 ± 9.1        | 54.3     | NA                 | 37.4 ± 17.3                            | NA                          | 56 ± 10                 | 49 ± 11                     |
| Johansson^29 | 2008 | 61.6 ± 8.3        | 48.0     | 60.0               | 31.5 ± 12.1                            | 4.8 ± 4.2                   | 62 ± 7                  | 73 ± 13                     |
| Moita^30     | 2008 | 64.3 ± 8.7        | 94.5     | NA                 | 56.0 ± 23.6                            | 12.4 ± 9.2                  | 46 ± 12                 | 41 ± 14                     |
| Niewoehner^24| 2005 | 67.9 ± 8.6        | 99.0     | 30.0               | 68.4 ± 36.0                            | 12.1 ± 10.5                 | 48 ± 11                 | 36 ± 13                     |
| Tashkin^14   | 2008 | 64.5 ± 8.4        | 74.7     | 29.6               | 48.7 ± 28.0                            | 9.8 ± 7.5                   | 42 ± 10                 | 39 ± 14                     |
| Tonnel^31    | 2008 | 64.2 ± 9.9        | 86.0     | 27.0               | 43.7 ± 21.9                            | 8.0 ± 7.8                   | 55 ± 11                 | 47 ± 13                     |
| Verkindre^26 | 2006 | 60.4 ± 9.9        | 94.0     | 28.5               | 43.7 ± 20.6                            | 9.3 ± 6.8                   | NA                      | 35 ± 9                      |
| Vogelmeier^32| 2008 | 62.6 ± 8.9        | 77.9     | NA                 | 38.0 ± 19.6                            | 7.0 ± 6.4                   | 54 ± 10                 | 51 ± 11                     |
| Voshaar^33   | 2008 | 64.0 ± 8.8        | 69.3     | 39.3               | 51.0 ± 29.0                            | 9.8 ± 7.8                   | 48 ± 12                 | 41 ± 12                     |

FVC = forced vital capacity
NA = no data available

Fig. 2. Effects of tiotropium versus placebo on health-related quality of life, measured with St George's Respiratory Questionnaire.

이 그림은 St George's Respiratory Questionnaire (SGRQ)로 측정한 건강 관련 삶의 질에 대한 티오트로피움과 위약의 효과를 보여주는 포레스트 플롯입니다.
각 연구(Brusasco^21 2003, Casaburi^19 2002, Chan^27 2007, Tashkin^14 2008, Tonnel^31 2008, Verkindre^26 2006)별로 티오트로피움 군과 위약 군의 참여자 수(n/N), OR(95% CI), Weight*% 값을 나타냅니다.
개별 연구의 효과 추정치는 사각형과 신뢰구간 선으로 표시됩니다. 사각형의 크기는 연구의 가중치(Weight*)를 나타냅니다.
총 이벤트 수는 티오트로피움 군 1765명, 위약 군 1087명입니다.
하단의 다이아몬드는 전체 효과(Subtotal (95% CI) OR 1.61, 95% Cl 1.38~1.88)를 나타내며, 1.0을 기준으로 "Favors Placebo"와 "Favors Tiotropium" 축에 따라 효과 방향을 보여줍니다.
전체 효과는 통계적으로 유의미합니다 (Test for overall effect: Z = 6.01, P < .001).
또한 이질성(Overall (I-squared = 41.6%, P = .13), Heterogeneity Chi^2 = 8.56 (df = 5)) 정보도 제공됩니다.

| Author, Year | Tiotropium (n/N) | Placebo (n/N) | Clinically Important Change in SGRQ | OR (95% CI) Random | Weight*% |
| :----------- | :--------------- | :-------------- | :---------------------------------- | :------------------- | :------- |
| Brusasco^21 2003 | 174/356          | 128/326         |                                     | 1.48 (1.09–2.00)     | 16.20    |
| Casaburi^19 2002 | 248/507          | 98/325          |                                     | 2.22 (1.65–2.98)     | 16.91    |
| Chan^27 2007   | 322/608          | 134/305         |                                     | 1.44 (1.09–1.89)     | 18.18    |
| Tashkin^14 2008 | 849/1887         | 593/1648        |                                     | 1.46 (1.27–1.67)     | 32.52    |
| Tonnel^31 2008 | 146/247          | 118/245         |                                     | 1.56 (1.09–2.22)     | 13.14    |
| Verkindre^26 2006 | 26/44            | 16/46           |                                     | 2.71 (1.15–6.36)     | 3.06     |
| Subtotal (95% CI) | 3649             | 2895            |                                     | 1.61 (1.38–1.88)     | 100      |

Total events: 1765 (tiotropium), 1087 (placebo)
Overall (I-squared = 41.6%, P = .13)
Heterogeneity Chi^2 = 8.56 (df = 5)
Test for overall effect: Z = 6.01, P < .001

* Weights are from random effects analysis

<PAGE>103